Evotec completes phase 1 trial for EVT 101 to treat Alzheimer's disease, neuropathic pain

By E. Janene Geiss

Philadelphia, Aug. 8 - Evotec AG announced Tuesday the successful completion of a phase 1 clinical trial with EVT 101, an NR2B subtype-specific NMDA receptor antagonist for the treatment of Alzheimer's disease and neuropathic pain.

A total of 90 healthy, young and elderly subjects received single and multiple ascending doses of the compound, according to a company news release.

In all subjects, EVT 101 was well-absorbed, achieved good exposure levels and was very well-tolerated with no significant adverse events, the company said.

In both the young and elderly subjects, the compound had a good pharmacokinetic profile, with an 11-hour half-life consistent with once- or twice-daily oral dosing.

The good tolerability of EVT 101 is significant given the unfavorable side-effect profile of non-selective NMDA antagonists, officials said.

Evotec is a Hamburg, Germany, biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.